PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs PFE |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.8 | 149.5% | -99% |
| LLY | Eli Lilly and Company | 1.55 | 42.6 | 27.5% | -87% |
| MRK | Merck & Co., Inc. | 1.74 | 36.8 | 21.2% | -86% |
| BMY | Bristol-Myers Squibb Company | 3.37 | 17.6 | 5.2% | -72% |
| AMGN | Amgen Inc. | 8.92 | 26.2 | 2.9% | -27% |